Michael Blum
Net worth: 8 912 $ as of 2024-03-30
Profile
Michael Blum worked as the Head of Market Access at Sarepta Therapeutics, Inc. from 2013 to 2015.
He then served as the Head of Commercial Operations at Zafgen, Inc. from 2015 to 2017.
Most recently, he held the position of Senior Vice President of Commercial Strategy at Homology Medicines, Inc. from 2020 to 2022.
Mr. Blum completed his undergraduate degree at the College of the Holy Cross in 1989 and earned an MBA from Babson College in 2001.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0.00% | 2023-02-22 | 523 ( 0.00% ) | 8 912 $ | 2024-03-30 |
Former positions of Michael Blum
| Companies | Position | End |
|---|---|---|
| LARIMAR THERAPEUTICS, INC. | Corporate Officer/Principal | 2017-10-31 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 2015-03-31 |
| Q32 BIO INC. | Corporate Officer/Principal | - |
Training of Michael Blum
| College of the Holy Cross (Massachusetts) | Undergraduate Degree |
| Babson College | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Homology Medicines, Inc.
 Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
- Stock Market
- Insiders
- Michael Blum
